1000, TEVA Pharmaceuticals Polska Sp. z o.o., Warsaw, Poland) containing 1000 mg of calcium carbonate, including 400 mg of elemental calci um) or placebo (lactose) were given to the partic ipants, with the first dose administered shortly after completion of the first series of SPTs fol lowed by 3 capsules a day for 3 days, according to the manufacturer's recommendation on the max imum dosage. We decided to use calcium carbon ate because it contains the highest proportion of calcium and is generally well tolerated, although with lower bioavailability. 16, 17 At visits V0, V1, and V2, all participants were subjected to SPTs, performed according to the EAACI guidelines, using 11 standard aero allergens (Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat allergens, dog aller gens, alder, birch, hazel, grass and cereals, Artemisia, Alternaria alternata, and Cladosporium herbarum). 15 Fifteen minutes after the inoculation of an allergen solution, wheal formation was re corded by outlining the contours with a black ink pen on a transparent tape, and measuring the longest wheal diameter. The test was consid ered positive when the wheal diameter was equal to or greater than 3 mm. SPTs were conducted by 2 trained investigators blinded to the study groups. Histamine (1.7 mg/ml of histamine hy drochloride, equal to 1 mg/ml of histamine) was a positive control, and a diluent was a negative control (both Allergopharma J. Ganzer KG, Re inbeck, Germany).
Visits V0 and V2 were scheduled in the morn ing (8-11 AM), and visit V1, 4 hours after visit V0. To avoid a possible overlap between wheals, the forearms were alternated for the successive SPTs and the injection sites corresponded to base line in each sequence.
Skin reactivity was also evaluated subjectively using the visual analog scale (VAS) to assess pru ritus intensity. The VAS consisted of a 10 cm line marked by the label "no itch" at one end, and by the label "very strong itch, as bad as could possi bly be" at the other. Pruritus was scored from 0 (no pruritus) to 10 (maximum pruritus). Partici pants were asked to assess pruritus intensity 15 minutes after each SPT.
The size of the wheal in the SPTs and itching sensation afterwards in relation to placebo were the primary endpoints of this study. Adverse ef fects of the medications used were also recorded.
A sample size of 40 participants was computed with an assumption to obtain a 95% power to de tect a between drug difference of 20% in the in hibition of the wheal size (caused both by hista mine and allergens) with an α error of 5% (the sample size was calculated using an online calcu lator: clincalc.com).
The values obtained for each measurement at 4 and 72 hours were compared with the base line values. Responses with a mean wheal diame ter of less than 3 mm were not included in the sta tistical analysis. The percentage change in wheal diameter was calculated (% change = [(baseline action has not been explained so far, and there have been no well designed, controlled stud ies. 10 Despite the lack of evidence, the The study group included adults suspected of pollen induced allergic rhinitis or allergic rhino conjunctivitis (or both) with or without asthma. Patients who tested positive to at least 1 aeroal lergen in the SPT (wheal diameter ≥3 mm) were included in the study.
The exclusion criteria were as follows: an intake of medication that interfered with skin reactivi ty (oral antihistamines, anxiolytics, and antide pressants) and other conditions that might reduce the safety of SPT or calcium supplementation or interfere with SPT results (according to the Eu ropean Academy of Allergy and Clinical Immu nology [EAACI]), including hypercalcemia, hyper calciuria, the use of cardiac glycosides or calcium channel blockers, lactose intolerance, kidney fail ure, pregnancy, and breastfeeding. 15 Topical ap plication of corticosteroids or calcineurin inhib itors on the volar forearms had to be discontin ued for at least 2 weeks before testing. None of these agents were permitted during the study. In dividuals with active skin disease, urticaria, der mographism, or those receiving ultraviolet light treatment were also excluded.
Three study visits were scheduled: V0 (screen ing visit), V1 (4 hours after the administration of the first dose), and V2 (3 days after the study initiation). Visits V0 and V2 were scheduled in the morning (8-11 AM), and visit V1, 4 hours af ter visit V0. After the screening visit (V0), par ticipants who met the inclusion criteria were ran domly assigned to groups in a 1:1 ratio, using a computer generated randomization schedule. A random block size between 4 and 8 was gener ated. Patients were randomly allocated to one of the treatment groups by assigning personal num bers in a consecutive and ascending order. Blind ing of the patients and investigators was ensured by the identical size, shape, weight, color, taste, and smell of the study medication and packaging.
After visit V0, participants received oral calci um capsules or placebo to be taken 3 times a day for 3 days (FIGuRE 1). Calcium carbonate (Calperos dIsCussION The use of calcium in allergic dis eases is controversial. Despite the lack of evi dence, its application in allergy related skin reac tions is relatively common in Central and Eastern Europe, especially in Poland, Czech Republic, Ger many, Hungary, Bulgaria, Slovenia, and Ukraine (a social media based survey prior to the study initiation; data not shown). On the other hand, calcium salts were found to interact with many drugs, both by alterations in gastric pH and by formation of nonabsorbable complexes.
8,18 These compounds were found to impair the absorp tion of prednisone and probably other cortico steroids used to treat symptoms of allergic reac tions; therefore, their extensive use may signifi cantly decrease corticosteroid activity. 5, 6 In this study, we addressed the question of the useful ness of calcium preparations in allergy related skin reactions by using objective and restric tive principles of a randomized controlled tri al in a reliable research model. 19 We found that calcium supplements given at a single dose or as a 3 day treatment did not reduce the size of the wheal or pruritus compared with placebo in a human SPT model.
Of note, the levels of calcium in intracellular compartments are 20 000 times lower than those in extracellular compartments.
20 Therefore, in vi tro experiments showing calcium mediated inhi bition of histamine release are not reproducible in vivo, since very high intracellular concentra tions are unlikely to be obtained, even following an intravenous administration.
10
Our results are inconsistent with those of pre vious studies conducted in the 1970s and 1980s, in which the authors observed the efficacy of cal cium in inhibiting type I allergic reactions. In the first report, Debelic 21 evaluated the effects of oral calcium gluconate and calcium lactate combined with vitamin D 2 on SPT results in 20 pollen allergic volunteers in a double blind ran domized controlled study, indicating a signifi cant wheal reduction (20%). A doubleblind ran domized study by Haas 22 revealed that the same mixture of ingredients fortified with ascorbic acid was effective in reducing the wheal area and wheal diameter -wheal diameter time t) / wheal diameter baseline] × 100) for each test group for all time periods and compared with one another. The same method was used to calculate the per centage change of itching.
Statistical comparisons between the groups were performed using 1way analysis of vari ance. A P value of less than 0.05 was considered statistically significant. The data were present ed as the means and standard error (all comput ed with Statistica Version 13.2, Statistica, Tulsa, Oklahoma, United States).
The study was conducted in accordance with the Declaration of Helsinki, good clinical prac tice guidelines, and the requirements of nation al laws. All study documents were approved by an independent ethical committee (the primary responsible ethics committee: Medical Universi ty of Warsaw; number, 205/2014). All patients gave their written informed consent to partici pate in the study.
REsuLTs
In total, 78 volunteers were screened for this study. Of these, 40 individuals (12 men and 28 women; mean age, 25 years; range, 19-32 years) who met all the inclusion criteria were enrolled and randomized, and all of them com pleted the study. No dropouts were recorded. At baseline, there was no significant difference be tween the groups in mean wheal responses and itching sensations in SPTs.
Neither the mean wheal diameter nor itching sensation changed in any of the groups through out the study compared with the baseline values (FIGuRE 2A and 2b, FIGuRE 3, TAbLEs 1 and 2) . There was no difference between the calcium and pla cebo groups in the percentage change in wheal response at any time point (V1, V2), compared with the baseline values (TAbLE 1). Moreover, there were no significant differences in itching sensa tion assessed using the VAS between the calcium preparation and placebo groups (TAbLE 2) .
Calcium carbonate was well tolerated when used at high doses, and no drug induced adverse effects were observed. FIGuRE 1 Study flowchart: calcium carbonate (1000 mg) or placebo were given to volunteers 3 times a day for 3 days. Skin prick tests were performed at baseline (V0), 4 hours after the intake of the first dose (V1), and 3 days later (V2), when all doses of the drugs were administered.
calcium levels occur 2 to 6 hours after calcium in gestion, 24,25 while in the above reports, calcium induced responses were recorded 10 and 30 min utes after administration.
21,22 Based on the anti histamine model, even when the maximum plas ma level of the drug is reached by 30 minutes, it takes another 1.5 hours for the drug to diffuse into the extravascular space to observe clinical effect.
26
itching intensity. However, the methodology of both studies raises some concerns. The authors of both papers did not adequately address SPT re producibility in their reports. There are many fac tors known to modulate the SPT readout, which are required to obtain reproducible results, and in our study, we strictly conformed to those cri teria.
23 Moreover, considering calcium pharmaco kinetics and bioavailability, the maximum serum an effect resulting from the inhibition of hista mine release from mast cells.
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In the 3 studies discussed above, calcium prep aration was administered in a single oral dose, much higher than that used in our study or than doses commonly administered to patients in or der to mitigate the symptoms of allergy. It is worth noting that calcium absorption is a satu rable process, which means that a dose of about 500 mg of elemental calcium results in a signifi cantly reduced absorption. 32 Furthermore, dur ing our 3 day study, the total dose administered in participants was 3.6 fold higher than the dose Our results are also in contrast to 2 studies con ducted by Bachert et al, 27 ,28 who analyzed the ef fects of intravenous and oral calcium on nasal al lergen provocation tests. The authors observed decreased swelling of the nasal mucosa and im proved nasal flow after calcium application, but interestingly, those effects were associated with only a minimum (4.5%) increase in serum calci um levels. The discrepancy between these studies and our findings is probably related to the study model. It may be speculated that calcium activity in allergic rhinitis most probably relies on the re duction in the permeability of blood vessel walls, in the Bachert's study, 27 and no antiallergic ef fects were observed, which makes this discrep ancy even more intriguing. A few more studies on this subject can be found in non English literature. They evaluated the effi cacy of oral or intravenous calcium preparations in allergic diseases such as allergic rhinitis, ur ticaria, and allergic bronchial asthma; however, their results are inconsistent. [33] [34] [35] Our study has several limitations. Firstly, this was not a clinical trial, but rather a human model study. The suppression of histamine induced skin wheals has been well established as an ob jective in vivo model for evaluating peripheral H 1 blockade 19 ; however, it does not necessarily reflect the overall antiallergic activity. Mediators other than histamine also play an important role in allergic cutaneous responses, including medi ators involved in cellular late phase responses. 36 Therefore, SPT findings should be interpreted with caution and with consideration of the clini cal situation since they may not necessarily cor relate with clinical responses. 37 The advantage of these tests is that they are easy to perform, fast, inexpensive, and safe. The SPT is used as an objective assessment of the efficacy and pharmacodynamics of antihis taminic drugs; however, its readout is still prone to errors. 38 Therefore, another limitation of our study was the subjective and manual method for SPT readouts, even though this part was performed by investigators blinded to the study groups. An automatic wheal measurement might be more accurate, but it is not available yet.
39
Conclusions To our knowledge, this is the only reliable report investigating the activity of calci um preparations in allergic reactions. In this pa per, we ultimately question any applicability of calcium preparations in the treatment of allergy. Our results show that neither single doses nor long term treatment with calcium supplements reduces allergic cutaneous reactions (measured as the wheal response and symptoms of pruri tus), as compared with placebo.
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